Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022 , Hubei, China.
BMC Neurol. 2012 Sep 20;12:97. doi: 10.1186/1471-2377-12-97.
Levetiracetam (LEV) is an antiepileptic drug with a favorable tolerability and safety profile with little or no effect on liver function.
Here, we reported an epileptic pediatric patient who developed a significant elevation in serum alkaline phosphatase level (ALP) during LEV monotherapy. Moreover, the serum ALP level was surprisingly decreased to normal after LEV discontinuation. The Naranjo Adverse Drug Reaction Probability Scale score was 6, indicating firstly LEV was a probable cause for the increased serum ALP.
Cautious usage and concerns of the LEV-associated potential ALP elevation should be considered when levetiracetam is prescribed to epilepsy patients, especially pediatric patients.
左乙拉西坦（LEV）是一种抗癫痫药物，具有良好的耐受性和安全性，对肝功能影响很小或没有影响。
在这里，我们报告了一例癫痫儿科患者，在 LEV 单药治疗期间，血清碱性磷酸酶（ALP）水平显著升高。此外，LEV 停药后，血清 ALP 水平出人意料地降至正常。Naranjo 药物不良反应概率量表评分为 6 分，表明 LEV 首先可能是导致血清 ALP 升高的原因。
当为癫痫患者，特别是儿科患者开具左乙拉西坦时，应谨慎使用并关注 LEV 相关的潜在 ALP 升高。
